title: Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior.
abstract: Adult neurogenesis has been implicated in affective disorders and the action of antidepressants (ADs) although the functional significance of this association is still unclear. The use of animal models closely mimicking human comorbid affective and anxiety disorders seen in the majority of patients should provide relevant novel information. Here, we used a unique genetic mouse model displaying higher trait anxiety (HAB) and comorbid depression-like behavior. We demonstrate that HABs have a lower rate of hippocampal neurogenesis and impaired functional integration of newly born neurons as compared with their normal anxiety/depression-like behavior (NAB) controls. In HABs, chronic treatment with the AD fluoxetine alleviated their higher depression-like behavior and protected them from relapse for 3 but not 7 weeks after discontinuation of the treatment without affecting neurogenesis. Similar to what has been observed in depressed patients, fluoxetine treatment induced anxiogenic-like effects during the early treatment phase in NABs along with a reduction in neurogenesis. On the other hand, treatment with AD drugs with a particularly strong anxiolytic component, namely the neurokinin-1-receptor-antagonist L-822 429 or tianeptine, increased the reduced rate of neurogenesis in HABs up to NAB levels. In addition, challenge-induced hypoactivation of dentate gyrus (DG) neurons in HABs was normalized by all three drugs. Overall, these data suggest that AD-like effects in a psychopathological mouse model are commonly associated with modulation of DG hypoactivity but not neurogenesis, suggesting normalization of hippocampal hypoactivity as a neurobiological marker indicating successful remission. Finally, rather than to higher depression-related behavior, neurogenesis seems to be linked to pathological anxiety.
authors.affiliation: Department of Pharmacology and Toxicology, Institute of Pharmacy and Centre for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Sah
authors.forename: C
authors.initials: C
authors.lastname: Schmuckermair
authors.forename: S B
authors.initials: SB
authors.lastname: Sartori
authors.forename: S
authors.initials: S
authors.lastname: Gaburro
authors.forename: M
authors.initials: M
authors.lastname: Kandasamy
authors.forename: R
authors.initials: R
authors.lastname: Irschick
authors.forename: L
authors.initials: L
authors.lastname: Klimaschewski
authors.forename: R
authors.initials: R
authors.lastname: Landgraf
authors.forename: L
authors.initials: L
authors.lastname: Aigner
authors.forename: N
authors.initials: N
authors.lastname: Singewald
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D001522:Behavior, Animal; D015415:Biomarkers; D018891:Dentate Gyrus / Q000187:drug effects* / Q000473:pathology; D003863:Depression / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D004195:Disease Models, Animal; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D055495:Neurogenesis / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology; D012008:Recurrence; D012074:Remission Induction; D013841:Thiazepines / Q000494:pharmacology
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; C532739:N-((2-cyclopropoxy-5-(5-trifluomethyl)tetrazol-1-yl)benzyl)-2-phenylpiperidin-3-amine; D010880:Piperidines; D013841:Thiazepines; D005473:Fluoxetine; C050504:tianeptine